Watch Congressional Hearings Expose PBM Tactics: This week, Heather Bresch, Mylan’s CEO, took shots from members of the House Oversight and Government Reform Committee for over five hours regarding the price of EpiPens. Members of the Oversight and Government Reform Committee were trying to get a handle on the prescription pricing model. Rep. Buddy Carter (R-Ga.) repeatedly asked Bresch to share details about the rebate deals with PBMs: https://www.youtube.com/watch?v=W_LVOYp6dOc. A hearing of the House Judiciary Committee focused on competition for medication to treat opioid addictions. Rep. Doug Collins (R-Ga.) challenged PCMA regarding conflicts of interest and spread pricing: https://www.youtube.com/watch?v=domoBhKKaMI. NCPA met in advance of the hearings with Committee staff and Members of Congress to discuss the role that PBMs play in the rising cost of medications and the importance of exposing PBM tactics.